Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.

Also called NCT01811485

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 171 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01811485
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01811485. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2015-02-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
Acronym
CLMF237A1303
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
LMF237 50/250 mg
Intervention (Drug)
LMF237 50/500 mg
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01811485
Content hash
d6fb66a507b4e533864252bd6ab6ed7d265c8462e3df3510104c1fdc3936fddd